Cargando…

No Evidence of Harms of Probiotic Lactobacillus rhamnosus GG ATCC 53103 in Healthy Elderly—A Phase I Open Label Study to Assess Safety, Tolerability and Cytokine Responses

BACKGROUND: Although Lactobacillus rhamnosus GG ATCC 53103 (LGG) has been consumed by 2 to 5 million people daily since the mid 1990s, there are few clinical trials describing potential harms of LGG, particularly in the elderly. OBJECTIVES: The primary objective of this open label clinical trial is...

Descripción completa

Detalles Bibliográficos
Autores principales: Hibberd, Patricia L., Kleimola, Lauren, Fiorino, Anne-Maria, Botelho, Christine, Haverkamp, Miriam, Andreyeva, Irina, Poutsiaka, Debra, Fraser, Claire, Solano-Aguilar, Gloria, Snydman, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249962/
https://www.ncbi.nlm.nih.gov/pubmed/25438151
http://dx.doi.org/10.1371/journal.pone.0113456
_version_ 1782346922771611648
author Hibberd, Patricia L.
Kleimola, Lauren
Fiorino, Anne-Maria
Botelho, Christine
Haverkamp, Miriam
Andreyeva, Irina
Poutsiaka, Debra
Fraser, Claire
Solano-Aguilar, Gloria
Snydman, David R.
author_facet Hibberd, Patricia L.
Kleimola, Lauren
Fiorino, Anne-Maria
Botelho, Christine
Haverkamp, Miriam
Andreyeva, Irina
Poutsiaka, Debra
Fraser, Claire
Solano-Aguilar, Gloria
Snydman, David R.
author_sort Hibberd, Patricia L.
collection PubMed
description BACKGROUND: Although Lactobacillus rhamnosus GG ATCC 53103 (LGG) has been consumed by 2 to 5 million people daily since the mid 1990s, there are few clinical trials describing potential harms of LGG, particularly in the elderly. OBJECTIVES: The primary objective of this open label clinical trial is to assess the safety and tolerability of 1×10(10) colony forming units (CFU) of LGG administered orally twice daily to elderly volunteers for 28 days. The secondary objectives were to evaluate the effects of LGG on the gastrointestinal microbiome, host immune response and plasma cytokines. METHODS: Fifteen elderly volunteers, aged 66–80 years received LGG capsules containing 1×10(10) CFU, twice daily for 28 days and were followed through day 56. Volunteers completed a daily diary, a telephone call on study days 3, 7 and 14 and study visits in the Clinical Research Center at baseline, day 28 and day 56 to determine whether adverse events had occurred. Assessments included prompted and open-ended questions. RESULTS: There were no serious adverse events. The 15 volunteers had a total of 47 events (range 1–7 per volunteer), 39 (83%) of which were rated as mild and 40% of which were considered related to consuming LGG. Thirty-one (70%) of the events were expected, prompted symptoms while 16 were unexpected events. The most common adverse events were gastrointestinal (bloating, gas, and nausea), 27 rated as mild and 3 rated as moderate. In the exploratory analysis, the pro-inflammatory cytokine interleukin 8 decreased during LGG consumption, returning towards baseline one month after discontinuing LGG (p = 0.038) while there was no difference in other pro- or anti-inflammatory plasma cytokines. CONCLUSIONS: Lactobacillus rhamnosus GG ATCC 53103 is safe and well tolerated in healthy adults aged 65 years and older. TRIAL REGISTRATION: ClinicalTrials.gov NCT 01274598
format Online
Article
Text
id pubmed-4249962
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-42499622014-12-05 No Evidence of Harms of Probiotic Lactobacillus rhamnosus GG ATCC 53103 in Healthy Elderly—A Phase I Open Label Study to Assess Safety, Tolerability and Cytokine Responses Hibberd, Patricia L. Kleimola, Lauren Fiorino, Anne-Maria Botelho, Christine Haverkamp, Miriam Andreyeva, Irina Poutsiaka, Debra Fraser, Claire Solano-Aguilar, Gloria Snydman, David R. PLoS One Research Article BACKGROUND: Although Lactobacillus rhamnosus GG ATCC 53103 (LGG) has been consumed by 2 to 5 million people daily since the mid 1990s, there are few clinical trials describing potential harms of LGG, particularly in the elderly. OBJECTIVES: The primary objective of this open label clinical trial is to assess the safety and tolerability of 1×10(10) colony forming units (CFU) of LGG administered orally twice daily to elderly volunteers for 28 days. The secondary objectives were to evaluate the effects of LGG on the gastrointestinal microbiome, host immune response and plasma cytokines. METHODS: Fifteen elderly volunteers, aged 66–80 years received LGG capsules containing 1×10(10) CFU, twice daily for 28 days and were followed through day 56. Volunteers completed a daily diary, a telephone call on study days 3, 7 and 14 and study visits in the Clinical Research Center at baseline, day 28 and day 56 to determine whether adverse events had occurred. Assessments included prompted and open-ended questions. RESULTS: There were no serious adverse events. The 15 volunteers had a total of 47 events (range 1–7 per volunteer), 39 (83%) of which were rated as mild and 40% of which were considered related to consuming LGG. Thirty-one (70%) of the events were expected, prompted symptoms while 16 were unexpected events. The most common adverse events were gastrointestinal (bloating, gas, and nausea), 27 rated as mild and 3 rated as moderate. In the exploratory analysis, the pro-inflammatory cytokine interleukin 8 decreased during LGG consumption, returning towards baseline one month after discontinuing LGG (p = 0.038) while there was no difference in other pro- or anti-inflammatory plasma cytokines. CONCLUSIONS: Lactobacillus rhamnosus GG ATCC 53103 is safe and well tolerated in healthy adults aged 65 years and older. TRIAL REGISTRATION: ClinicalTrials.gov NCT 01274598 Public Library of Science 2014-12-01 /pmc/articles/PMC4249962/ /pubmed/25438151 http://dx.doi.org/10.1371/journal.pone.0113456 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Hibberd, Patricia L.
Kleimola, Lauren
Fiorino, Anne-Maria
Botelho, Christine
Haverkamp, Miriam
Andreyeva, Irina
Poutsiaka, Debra
Fraser, Claire
Solano-Aguilar, Gloria
Snydman, David R.
No Evidence of Harms of Probiotic Lactobacillus rhamnosus GG ATCC 53103 in Healthy Elderly—A Phase I Open Label Study to Assess Safety, Tolerability and Cytokine Responses
title No Evidence of Harms of Probiotic Lactobacillus rhamnosus GG ATCC 53103 in Healthy Elderly—A Phase I Open Label Study to Assess Safety, Tolerability and Cytokine Responses
title_full No Evidence of Harms of Probiotic Lactobacillus rhamnosus GG ATCC 53103 in Healthy Elderly—A Phase I Open Label Study to Assess Safety, Tolerability and Cytokine Responses
title_fullStr No Evidence of Harms of Probiotic Lactobacillus rhamnosus GG ATCC 53103 in Healthy Elderly—A Phase I Open Label Study to Assess Safety, Tolerability and Cytokine Responses
title_full_unstemmed No Evidence of Harms of Probiotic Lactobacillus rhamnosus GG ATCC 53103 in Healthy Elderly—A Phase I Open Label Study to Assess Safety, Tolerability and Cytokine Responses
title_short No Evidence of Harms of Probiotic Lactobacillus rhamnosus GG ATCC 53103 in Healthy Elderly—A Phase I Open Label Study to Assess Safety, Tolerability and Cytokine Responses
title_sort no evidence of harms of probiotic lactobacillus rhamnosus gg atcc 53103 in healthy elderly—a phase i open label study to assess safety, tolerability and cytokine responses
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249962/
https://www.ncbi.nlm.nih.gov/pubmed/25438151
http://dx.doi.org/10.1371/journal.pone.0113456
work_keys_str_mv AT hibberdpatricial noevidenceofharmsofprobioticlactobacillusrhamnosusggatcc53103inhealthyelderlyaphaseiopenlabelstudytoassesssafetytolerabilityandcytokineresponses
AT kleimolalauren noevidenceofharmsofprobioticlactobacillusrhamnosusggatcc53103inhealthyelderlyaphaseiopenlabelstudytoassesssafetytolerabilityandcytokineresponses
AT fiorinoannemaria noevidenceofharmsofprobioticlactobacillusrhamnosusggatcc53103inhealthyelderlyaphaseiopenlabelstudytoassesssafetytolerabilityandcytokineresponses
AT botelhochristine noevidenceofharmsofprobioticlactobacillusrhamnosusggatcc53103inhealthyelderlyaphaseiopenlabelstudytoassesssafetytolerabilityandcytokineresponses
AT haverkampmiriam noevidenceofharmsofprobioticlactobacillusrhamnosusggatcc53103inhealthyelderlyaphaseiopenlabelstudytoassesssafetytolerabilityandcytokineresponses
AT andreyevairina noevidenceofharmsofprobioticlactobacillusrhamnosusggatcc53103inhealthyelderlyaphaseiopenlabelstudytoassesssafetytolerabilityandcytokineresponses
AT poutsiakadebra noevidenceofharmsofprobioticlactobacillusrhamnosusggatcc53103inhealthyelderlyaphaseiopenlabelstudytoassesssafetytolerabilityandcytokineresponses
AT fraserclaire noevidenceofharmsofprobioticlactobacillusrhamnosusggatcc53103inhealthyelderlyaphaseiopenlabelstudytoassesssafetytolerabilityandcytokineresponses
AT solanoaguilargloria noevidenceofharmsofprobioticlactobacillusrhamnosusggatcc53103inhealthyelderlyaphaseiopenlabelstudytoassesssafetytolerabilityandcytokineresponses
AT snydmandavidr noevidenceofharmsofprobioticlactobacillusrhamnosusggatcc53103inhealthyelderlyaphaseiopenlabelstudytoassesssafetytolerabilityandcytokineresponses